SBIR/STTR Research Award

Cell-penetrating peptides for enhanced delivery of CRISPR/Cas

Award identifier e2eb31ad84bf6c758d9b5cc7136fde77b20de2a837df488a765472b99844c0e4Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$223,122

Program and phase

SBIR · Phase I

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
New Echota Biotechnology
Proposal award date
2018-06-01
Contract end date
2019-01-31
UEI
UN6JWBW8FPS5
Solicitation number
PA17-302
Topic code
400

Research abstract

PROJECT SUMMARYNew Echota Biotechnology proposes to wed two highly promising technologiesCRISPR Cas genome editing and cell penetrating peptidesCPPsto enhance genome editing in a wide array of cell linestissues and organismsCPPs are capable of mediating penetration of the plasma membraneallowing delivery of macromolecular cargos to the cell interiorCPP delivery of cargos to the interior compartments of cells is a potentially transformative platform technology for the development of therapeuticsdiagnostics and research toolsThis SBIR Phaseapplication proposes to develop an enhanced CRISPR Casproduct based on our novel CPP adaptor technologyOur innovative approach to cargo delivery is the use of high affinity but reversible noncovalent binding to attach cargo to CPPsWe have designed CPP adaptor fusion proteins consisting of the cell penetrating moiety from HIV transactivator of transcription or other CPP fused to calmodulinCaMor other EF hand proteinsOur prototypes bind CaM binding siteCBScontaining cargos with nanomolar affinity in the presence of calcium but negligibly in its absenceBecause mammalian cells typically maintain low resting concentrations of calciumcargos dissociate from the CPP adaptor once inside the cellThe largest technical hurdle to development of CPP therapeutics is failure to escape from endosomesour technology solves this problemWe will deliver active CassgRNA complexes to the nuclei of mammalian cells using our proprietary CPPadaptor technologyand using an established CRISPR assayoptimize delivery for efficiency of easily assayable editingWe will then use the optimized conditions to perform proof of concept experimentsknocking out Fwhich encodes blood coagulation factor IXFIXdefects in which cause hemophilia BWe will also design and execute a small mouse study to demonstrate efficacy of our approach in animalsmodeling from a previous studies in which editing was effected via injection of CRISPR plasmids in tail veinsNew Echota Biotechnology sNEBsystem has speedsafety and efficiency advantages over competing methods and ease of use and dosing advantages over other CPP methodsThe significance of this application is that success will enable utilization of CPP adaptors to enhance CRISPR technology in a way that overcomes currently intractable limitations PROJECT NARRATIVE This project seeks to develop its core technology to enhance the delivery of CRISPR Cas gene editing components to living cells using cell penetrating peptides attached to adaptor molecules that bind payloads with high affinity and release them in the cell interiorCRISPR Cas is currently limited by the need to transfect or transduce components into cells which is often problematicSuccess will broaden the application of gene editing technology and further validate that our technology is an adaptable tool for delivery of a wide array of macromoleculespotentially improving the delivery of cancer therapeuticsantiviralsand proteins to ameliorate a variety of disorders as well as creating versatile research and diagnostic tools

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

2 SBIR/STTR records share this UEI (2015–2018). Reported award amounts total $449,917. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.